Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQ: CRNX · IEX Real-Time Price · USD
44.67
+0.23 (0.53%)
Mar 28, 2024, 10:37 AM EDT - Market open

Crinetics Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 20232022202120202019201820172016
Revenue
4.014.741.080.071.192.432.050.59
Revenue Growth (YoY)
-15.28%339.42%1418.31%-94.05%-50.86%18.73%247.20%-
Gross Profit
4.014.741.080.071.192.432.050.59
Selling, General & Admin
58.0942.3924.5318.0313.526.661.941.53
Research & Development
168.53130.2384.265741.5124.489.235.1
Operating Expenses
226.62172.62108.7875.0255.0331.1411.176.63
Operating Income
-222.61-167.88-107.7-74.95-53.83-28.71-9.13-6.04
Interest Expense / Income
00000000.01
Other Expense / Income
-8.08-3.96-0.06-1.14-3.41-1.60.03-0.04
Pretax Income
-214.53-163.92-107.64-73.81-50.42-27.12-9.16-6.02
Net Income
-214.53-163.92-107.64-73.81-50.42-27.12-9.16-6.02
Shares Outstanding (Basic)
58523830241211
Shares Outstanding (Diluted)
58523830241211
Shares Change
11.71%35.24%26.23%25.95%99.10%785.63%35.61%-
EPS (Basic)
-3.69-3.15-2.80-2.42-2.09-2.23-6.68-5.96
EPS (Diluted)
-3.69-3.15-2.80-2.42-2.09-2.23-6.68-5.96
Free Cash Flow
-171-116.86-89.02-62.21-46.87-20.52-9.78-5.66
Free Cash Flow Per Share
-2.94-2.25-2.32-2.04-1.94-1.69-7.14-5.60
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-5547.17%-3544.06%-9990.91%-105567.61%-4512.32%-1182.45%-446.31%-1026.15%
Profit Margin
-5345.85%-3460.38%-9985.25%-103960.56%-4226.49%-1116.76%-447.78%-1021.90%
Free Cash Flow Margin
-4261.03%-2466.98%-8258.26%-87623.94%-3929.00%-845.06%-478.39%-960.61%
EBITDA
-212.22-162.53-106.38-72.59-49.31-26.64-9.03-5.92
EBITDA Margin
-5288.34%-3431.05%-9868.18%-102233.80%-4133.19%-1097.36%-441.52%-1004.41%
Depreciation & Amortization
2.311.391.261.231.110.470.130.09
EBIT
-214.53-163.92-107.64-73.81-50.42-27.12-9.16-6.01
EBIT Margin
-5345.85%-3460.38%-9985.25%-103960.56%-4226.49%-1116.76%-447.78%-1020.03%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).